<div id="readability-page-1">11:24 AM EST, 12/30/2025 (MT Newswires) -- Genmab ( GMAB ) can expect a &#34;transformative&#34; year ahead, with five to six pivotal trial readouts for Epkinly, Rina-S and petosemtamab, Truist Securities said in note Tuesday.The company's recent decision to discontinue development of acasunlimab was disappointing, but should result in savings of about $100 million, which is expected to be redirected to the Rina-S and petosemtamab programs, according to the note.Considering that pivotal studies are already being conducted for Rina-S in ovarian and endometrial cancer, and for petosemtamab in head and neck cancer, Truist said the realigned funds are expected to focus more on exploring other potential indications for these assets.The brokerage said it updated its model to remove the projected revenue for acasunlimab and add potential Rina-S revenue in endometrial cancer, with the first commercial contribution expected in 2029.Truist maintained a buy rating on the stock, with a $48 price target.Shares of Genmab ( GMAB ) were down more than 2% in recent trading Tuesday.Price: 31.77, Change: -0.76, Percent Change: -2.32 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

GMAB

根據 Truist Securities 的報告，Genmab 在未來一年有望迎來 “變革性” 的發展，預計將有五到六項關鍵試驗結果發佈。儘管停止開發 acasunlimab 令人失望，但公司將節省約 1 億美元，並將資金重新分配到 Rina-S 和 petosemtamab 項目上。Rina-S 在卵巢癌和子宮內膜癌的關鍵研究正在進行中，而 petosemtamab 則在頭頸癌方面進行研究。Truist 維持對該公司的買入評級，目標價為 48 美元，儘管 Genmab 的股價最近下跌超過 2%

Truist Securities 表示，Genmab 面臨着一個'變革性'的一年，關鍵試驗結果即將揭曉